New diabetes clinical trial: A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Published on: July 03, 2019 at 07:00PM
Conditions:   Healthy Volunteers Diabetes Mellitus, Type 2;   Healthy Volunteers Overweight;   Healthy Volunteers Obesity
Interventions:   Drug: Semaglutide (administered by DV3396 pen);   Drug: Semaglutide (administered by PDS290 pen)
Sponsor:   Novo Nordisk A/S
Recruiting